UPDATED - Changes to the clinical management of women at Intermediate Risk within the National Cervical Screening Program
January 28, 2021
Changes to the Guidelines for the clinical management of women at Intermediate Risk of cervical cancer will come into effect from Monday, 1 February 2021.
This follows the Cancer Council Australia Clinical Guidelines working party review of national data from the first two years of the renewed program.
A review of the national clinical program data shows that women at Intermediate risk whose follow-up test is HPV (not-16/18) positive, Liquid Based Cytology prediction negative, possible or low grade squamous intraepithelial lesion will have a low likelihood of histologically-confirmed high grade squamous intraepithelial lesion (CIN2/3) or worse.
Please note that it is now recommended that:
Women with a 12-month follow up HPV (not-16/18) result with LBC prediction negative, pLSIL or LSIL (Intermediate risk result) should be recommended to undertake a further HPV follow up test in 12 months’ time following their previous HPV test instead of referral to colposcopy.
Some groups of women may be at higher risk of harbouring a high-grade abnormality and should be referred to colposcopy if HPV is detected at 12 months, regardless of the LBC result.
- Women two or more years overdue for screening at the time of the initial screen
- Women who identify as being of Aboriginal or Torres Strait Islander
- Women aged 50 years or older
For more information, please visit one of the sources below: